In a fresh disappointment, Amgen spotlights a major safety issue with KRAS combo

Amgen had hoped that its latest study matching its landmark KRAS G12C drug Lumakras with checkpoint inhibitors would open up its treatment horizons and expand its commercial potential. Instead the combo spurred safety issues that forced the pharma giant to alter course on its treatment strategy and blunted efficacy, onceā€¦


Click to view original post